WHO Stops The Use Of Hydroxychloroquine

0
109
53

The solidarity trial arm of the World Health Organization (WHO) has stopped the researches into the use of Hydroxychloroquine to effectively treat patients with COVID-19.

It said that several studies have indicated that Hydroxychloroquine (an anti-malaria drug) has no impact whatsoever on the virus, and does not result in the reduction of mortality of hospitalised COVID-19 patients.

This is coming days after U.S Food and Drug Administration (FDA) revoked the emergency authorisation for Hydroxychloroquine to treat hospitalized COVID-19 patients, amidst several evidences that it could cause serious side-effects, and that it does not work.

READ:  Trump Ends Donation To WHO

It said, “The Solidarity Trial’s Hydroxychloroquine arm is being stopped, on the basis of evidence showing it does not reduce mortality for hospitalised COVID-19 patients.”

On Tuesday, researchers at the University of Oxford in England reported that a commonly used steroid called dexamethasone can help COVID-19 patients on ventilators survive the illness, although the data from that trial have not be made public.

The WHO described the initial clinical trial results from dexamethasone as a welcome development, and can be lifesaving for treating patients who are critically ill with COVID-19.

READ:  Orji Uzor Kalu Is Out

It however said it will carry out an in-depth analysis of the intervention with the new drug, before issuing clinical guidance on how and when it should be used.

The WHO made this known yesterday in a statement.

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here